Literature DB >> 10853025

Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer.

A Seki1, M Yoshinouchi, N Seki, J Kodama, Y Miyagi, T Kudo.   

Abstract

We examined gene amplifications of the c-erbB-2 and FGF-3 gene in 48 epithelial ovarian cancers by differential PCR and addressed their association with clinico-pathological features including clinical outcome. Overall, 25.0 and 20.8% of ovarian cancers displayed amplified c-erbB-2 or FGF-3 gene, respectively. Amplification of the c-erbB-2 gene was significantly associated with particular histological cell types, higher histological grade, and low levels of serous CA125. However, there was no correlation between c-erbB-2 gene amplification and patient outcome. No correlation was observed between FGF-3 gene amplification and any clinico-pathological features including overall survival. These findings suggested that c-erbB-2 or FGF-3 gene amplification might be one of the oncogenic events implicated in the development of ovarian cancers, yet is not a useful prognostic marker.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10853025     DOI: 10.3892/ijo.17.1.103

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

1.  Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.

Authors:  Claire Cole; Sin Lau; Alison Backen; Andrew Clamp; Graham Rushton; Caroline Dive; Cassandra Hodgkinson; Rhona McVey; Henry Kitchener; Gordon C Jayson
Journal:  Cancer Biol Ther       Date:  2010-09-04       Impact factor: 4.742

2.  Rsf-1 overexpression serves as a prognostic marker in human hepatocellular carcinoma.

Authors:  Chengyao Xie; Lin Fu; Lingling Xie; Nan Liu; Qingchang Li
Journal:  Tumour Biol       Date:  2014-05-06

3.  Rsf-1 overexpression correlates with poor prognosis and cell proliferation in colon cancer.

Authors:  Shuli Liu; Qianze Dong; Enhua Wang
Journal:  Tumour Biol       Date:  2012-04-20

4.  Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker.

Authors:  Hui Li; Yi Zhang; Yue Zhang; Xue Bai; Yang Peng; Ping He
Journal:  Tumour Biol       Date:  2014-03-01

5.  Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.

Authors:  Peter Schraml; Georg Schwerdtfeger; Felix Burkhalter; Anna Raggi; Dietmar Schmidt; Teresa Ruffalo; Walter King; Kim Wilber; Michael J Mihatsch; Holger Moch
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

6.  Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater.

Authors:  Klaus L Prenzel; Ute Warnecke-Eberz; Jan Brabender; Stephan E Baldus; Elfriede Bollschweiler; Christian A Gutschow; Uta Drebber; Arnulf H Hoelscher; Paul M Schneider
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

7.  Upregulation of miR-31* is negatively associated with recurrent/newly formed oral leukoplakia.

Authors:  Wen Xiao; Zhe-Xuan Bao; Chen-Yang Zhang; Xiao-Yun Zhang; Lin-Jun Shi; Zeng-Tong Zhou; Wei-Wen Jiang
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

8.  HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab.

Authors:  Masaki Fujimura; Noriyuki Katsumata; Hiroshi Tsuda; Naoko Uchi; Satomi Miyazaki; Takao Hidaka; Masatoshi Sakai; Shigeru Saito
Journal:  Jpn J Cancer Res       Date:  2002-11

9.  Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a systematic review and meta-analysis.

Authors:  Kai Wang; Chenan Guan; Junhui Yu; Xiaoxiao Jin; Ling Sun; Lingzhi Zheng; Liang Xia; Yuquan Zhang
Journal:  Oncotarget       Date:  2017-09-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.